Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alcon Inc.
Akorn agrees with DoJ to pay $7.9m to settle allegations it deliberately sold three as Rx three ingredients moved to OTC. Mislabeling led Medicare Part D to pay for the drugs for around a year despite the products not being eligible for coverage.
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.
With the $770m acquisition, Alcon will gain two commercial eye drop products for glaucoma and a Phase III candidate for dry eye.
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
- OTC, Consumer
- Consumables, Central Supplies
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Alcon Laboratories, Inc.
- Alcon Universal SA
- Ivantis, Inc.